Novo Nordisk Partners with AWS to Establish AI Co-Innovation Center for Drug Discovery
Danish pharmaceutical giant Novo Nordisk has partnered with Amazon Web Services (AWS) to establish an AI co-innovation center at its London facility. The collaboration aims to leverage agentic AI and cloud technologies to accelerate drug discovery and modernize Novo Nordisk's operations. This partnership highlights the growing trend of integrating advanced AI and cloud computing into biotechnology to significantly reduce the time required to bring new drugs from target identification to clinical trials. By utilizing AWS's infrastructure, Novo Nordisk aims to streamline its R&D pipeline and address complex biological challenges more efficiently. Under the agreement, AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner. Novo Nordisk's R&D teams will collaborate directly with AWS engineers and AI scientists to shorten the timeline from drug target identification to first-in-human trials.
## BACKGROUND
Drug discovery is traditionally a lengthy and costly process, often taking over a decade to move from identifying a biological target to human trials. Agentic AI refers to autonomous AI systems capable of pursuing complex goals and making decisions, which, when combined with cloud-based machine learning, can analyze massive biological datasets to identify viable drug targets much faster than conventional methods.